Almay Clear Complexion Makeup

Salicylic Acid


Almay
Human Otc Drug
NDC 0311-0724
Almay Clear Complexion Makeup also known as Salicylic Acid is a human otc drug labeled by 'Almay'. National Drug Code (NDC) number for Almay Clear Complexion Makeup is 0311-0724. This drug is available in dosage form of Emulsion. The names of the active, medicinal ingredients in Almay Clear Complexion Makeup drug includes Salicylic Acid - 1 mg/mL . The currest status of Almay Clear Complexion Makeup drug is Active.

Drug Information:

Drug NDC: 0311-0724
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Almay Clear Complexion Makeup
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Salicylic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Almay
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Emulsion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SALICYLIC ACID - 1 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 16 Mar, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 10 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part358H
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:ALMAY
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:O414PZ4LPZ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0311-0724-0130 mL in 1 BOTTLE, GLASS (0311-0724-01)16 Mar, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose acne treatment

Product Elements:

Almay clear complexion makeup salicylic acid salicylic acid salicylic acid isodecyl neopentanoate lactobacillus acidophilus aloe vera leaf water caprylyl glycol cyclomethicone 5 dimethicone glycerin dimethicone/bis-isobutyl ppg-20 crosspolymer ferric oxide red ferric oxide yellow peg/ppg-18/18 dimethicone peg-10 dimethicone (600 cst) phenoxyethanol edetate sodium alpha-tocopherol acetate trimethylsiloxysilicate (m/q 0.6-0.8) cetyl peg/ppg-10/1 dimethicone (hlb 2) cyclomethicone 6 carnauba wax perlite smallanthus sonchifolius leaf .alpha.-glucan oligosaccharide boron nitride sea salt nylon-12 titanium dioxide triethoxycaprylylsilane zinc oxide trisiloxane ferrosoferric oxide lecithin, soybean maltodextrin

Indications and Usage:

Use helps clear and prevent new acne blemishes

Warnings:

Warnings for external use only. when using this product • skin irritation and dryness is more likely to occur if you use another topical acne mediation at the same time. if irritation occurs, only use one topical acne medication at a time. • avoid contact with eyes. if contact occurs, flush thoroughly with water

Dosage and Administration:

Directions apply evenly from center of face outwards. • clean skin thoroughly before applying this product. • cover entire affected area with a thin layer one to three times daily • because excessive drying of the skin may occur, start with one application daily, then gradually increase to two to three times daily if needed or as directed by a doctor. • if bothersome dryness or peeling occurs, reduce application to once a day or every other day. sensitivity test for a new user: apply product sparingly to one or two small affected areas during the first 3 days. if no discomfort occurs, follow the directions above.

Package Label Principal Display Panel:

Artwork almay cc makeup booklet


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.